Grant: Banting Postdoctoral Fellowship Program
Université de Montréal
$140,000.00
Validation of Rapid-Eye-Movement sleep quantitative electroencephalography as a non-invasive marker of cholinergic denervation and early Alzheimer's Disease neurodegeneration
EF 2017-18
Résumé
Alzheimer's Disease (AD) is the most common form of dementia, affecting one in 11 Canadians aged over 65 years. Many years prior to the onset of observable clinical manifestations, AD neurodegenerative processes are present under a silent, or pre-clinical, phase. To facilitate the development and assessment of therapeutic strategies, markers of the pre-clinical phase of AD are urgently needed.
Mild cognitive impairment (MCI) is a clinical syndrome characterized by the presence of objective cognitive deficits in the absence of functional incapacities. Individuals with amnestic MCI (aMCI) are at high risk of AD, with yearly conversion rates ranging from 20 to 50%. However, not all MCI individuals will develop AD over time. The MCI condition thus provides a unique opportunity to identify markers of impending AD.
Up to now, research has focused on markers measuring brain activity in awake patients. Here, we propose that rapid-eye-movement (REM) sleep is a more sensitive state than wakefulness to detect early stages of AD neurodegeneration. Indeed, during REM sleep, the activity of the cholinergic system, which undergoes some of the earliest and most salient biochemical changes in AD, is not masked by other systems that are active during wakefulness. Thus, REM sleep is likely to provide a more accurate estimate of cholinergic integrity and, consequently, improve the detection of early signs of AD neurodegeneration.
Accordingly, the goal of this project is to assess the predictive value of brain electrical activity during REM sleep, as compared to wakefulness, to differentiate patients with aMCI from normal controls. Using positron emission tomography (PET) imaging, we will also validate the association between brain electrical activity during REM sleep and cholinergic activity. If our hypotheses are confirmed, then REM sleep characteristics could be used to identify individuals at high risk of progressing to AD.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
374403
Name
Schoemaker-Marcotte Dorothée
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Validation of Rapid-Eye-Movement sleep quantitative electroencephalography as a non-invasive marker of cholinergic denervation and early Alzheimer's Disease neurodegeneration
Programtype2
Fellowship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Aging; Alzheimer'S Disease; Biomarker; Cholinergic System; Magnetic Resonance Imaging; Positron Emission Tomography; Quantitative Eeg; Rem Sleep
Abstract
Alzheimer's Disease (AD) is the most common form of dementia, affecting one in 11 Canadians aged over 65 years. Many years prior to the onset of observable clinical manifestations, AD neurodegenerative processes are present under a silent, or pre-clinical, phase. To facilitate the development and assessment of therapeutic strategies, markers of the pre-clinical phase of AD are urgently needed.
Mild cognitive impairment (MCI) is a clinical syndrome characterized by the presence of objective cognitive deficits in the absence of functional incapacities. Individuals with amnestic MCI (aMCI) are at high risk of AD, with yearly conversion rates ranging from 20 to 50%. However, not all MCI individuals will develop AD over time. The MCI condition thus provides a unique opportunity to identify markers of impending AD.
Up to now, research has focused on markers measuring brain activity in awake patients. Here, we propose that rapid-eye-movement (REM) sleep is a more sensitive state than wakefulness to detect early stages of AD neurodegeneration. Indeed, during REM sleep, the activity of the cholinergic system, which undergoes some of the earliest and most salient biochemical changes in AD, is not masked by other systems that are active during wakefulness. Thus, REM sleep is likely to provide a more accurate estimate of cholinergic integrity and, consequently, improve the detection of early signs of AD neurodegeneration.
Accordingly, the goal of this project is to assess the predictive value of brain electrical activity during REM sleep, as compared to wakefulness, to differentiate patients with aMCI from normal controls. Using positron emission tomography (PET) imaging, we will also validate the association between brain electrical activity during REM sleep and cholinergic activity. If our hypotheses are confirmed, then REM sleep characteristics could be used to identify individuals at high risk of progressing to AD.
Competitiondate
201709
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Schoemaker-Marcotte, Dorothée
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~